Vcare 2023 Annual Review
Published Time:
2024-02-07 17:49
Source:
I. Important Progress in Innovative Drug R&D
① Submitted NDA to US FDA for anti-platelet drug Vicagrel: If approved, it may benefit ~27.6M US patients with coronary heart disease/stroke.
② Completed 1st patient enrollment in China’s Phase II trial for anti-resistant TRK inhibitor VC004: Phase I data showed ORR of 80%-90% in NTRK fusion+ solid tumors and DOR up to 24 months.
③ Completed Phase II enrollment for 2nd-gen selective JAK1 inhibitor VC005 in ankylosing spondylitis: Preliminary blinded analysis showed favorable efficacy/safety.
Additionally: VC004 gel approved for clinical trials; VC005 gel initiated China Phase I for atopic dermatitis; Multiple preclinical projects advanced in cardio-cerebrovascular, oncology, and autoimmune fields.
II. CRO/CDMO Service Revenue
2023 external service revenue: ~RMB 400 million (+25.5% YoY); New contracts: >RMB 550 million (+16.1% YoY).
III. Production Base Development
① Tianshu Pharmaceutical Phase I facility operational: 240+ employees; Robust quality system established; Passed 30+ audits by global clients/regulators; Monthly output exceeded RMB 10M since July trial production, reaching RMB 35M in December.
② Obtained Drug Manufacturing Certificate: enabling compliant API and innovative drug CDMO production.
IV. Corporate Financing
Closed Series C financing >RMB 450 million amid market downturn: Named among 2023 Top 10 Pharma Financing Projects in China; Total financing 2021-2023: ~RMB 1B; Valuation >RMB 3B.
V. Employee Care
① Organized 6 cultural events
② Held 12 Happy Hour activities
③ Completed 60+ promotions & 80+ internal trainings
④ 60+ employees received 3rd equity incentive
VI. Awards & Honors
Jiangsu Vcare Honored As: Jiangsu Provincial Enterprise Technology Center; Jiangsu Science & Technology Second Prize
Nanjing Vcare Honored As: Top 20 CRO Enterprises in China; High-Tech Enterprise; Nanjing Innovative SME
Related News
30
2024
/
12
On December 30, 2024, the first administration of VC005 tablets was completed in the Phase III clinical trial of oral treatment of moderate-to-severe atopic dermatitis (AD). VC005 is a new-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare). Positive top-line data were obtained from the unblinded Phase II clinical study of VC005 for AD, with primary endpoints showing superiority over the best drugs in the same class. Meanwhile, the overall safety and tolerability of the drug are good. In particular, the decreases in neutrophil and platelet counts caused by high dosage VC005 were smaller, compared with the positive control group of tofacitinib, and no significant reduction in lymphocyte count was observed.
View Details
18
2024
/
11
Jiangsu Vcare Selected Among "2024 China’s Top 500 Hidden Unicorn Enterprises"
At the 2024 China Hidden Unicorn 500 Summit, theDevelopment Report on China’s Top 500 Hidden Unicorn Enterprises 2024was released.Jiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) debuted on this list, showcasing its strong technical accumulation and continuous innovation in independent R&D of innovative drugs and full-chain CRO/CDMO services for pharmaceuticals.
View Details
01
2024
/
11
Recently, the Nanjing Municipal Science and Technology Bureau announced the acceptance results of 2024 provincial-level engineering research centers and academician workstations. The"Jiangsu (Vcare) Chemical Innovative Drug Engineering Research Center", established byJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare), successfully passed project acceptance.
View Details
28
2024
/
10
Jiangsu Vcare Included in "2024 Jiangsu Provincial Sci-Tech Enterprise Listing Cultivation Program"
Recently, the Jiangsu Provincial Department of Science and Technology announced the "2024 Proposed Enterprises for Provincial Sci-Tech Enterprise Listing Cultivation Program," withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) successfully included.
View Details
23
2024
/
10
Jiangsu Vcare Selected Among "Top 100 China Pharma Innovation Seed Enterprises 2024"
Recently, the "Top 100 China Pharma Innovation Seed Enterprises 2024" list was released, withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) ranked in the second tier. This list, compiled by a non-governmental organization, evaluates enterprises based on innovation foundation, process, and outcomes—using patent data, clinical trial data, etc.—selected from over 5,000 Chinese pharmaceutical companies.
View Details
22
2024
/
10
Jiangsu Vcare's Oral Treatment VC005 for Atopic Dermatitis enters Phase III Clinical Study
VC005 tablets, developed by Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare), is a new-generation highly selective JAK1 inhibitor. The oral treatment of moderate-to-severe atopic dermatitis has initiated a Phase III clinical trial. It is a multicenter, randomized, double-blind, placebo parallel-controlled Phase III clinical study, aiming to evaluate the efficacy and safety of VC005 tablets for adult patients with moderate-to-severe atopic dermatitis. The trial is led by the Institute of Dermatology, Chinese Academy of Medical Sciences.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn